2Seventy Bio Inc


Prices are adjusted according to historical splits.

2Seventy Bio Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$260.90 million
Book Value:
Revenue TTM:
$147.25 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

2Seventy Bio Inc had its IPO on 2021-11-03 under the ticker symbol TSVT.

The company operates in the Healthcare sector and Biotechnology industry. 2Seventy Bio Inc has a staff strength of 425 employees.

Stock update

Shares of 2Seventy Bio Inc opened at $4.6 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $4.1 - $4.6, and closed at $4.16.

This is a -5.02% slip from the previous day's closing price.

A total volume of 2,064,060 shares were traded at the close of the day’s session.

In the last one week, shares of 2Seventy Bio Inc have slipped by -19.54%.

2Seventy Bio Inc's Key Ratios

2Seventy Bio Inc has a market cap of $260.90 million, indicating a price to book ratio of 1.4431 and a price to sales ratio of 8.24.

In the last 12-months 2Seventy Bio Inc’s revenue was $147.25 million with a gross profit of $-183458000 and an EBITDA of $-185862000. The EBITDA ratio measures 2Seventy Bio Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, 2Seventy Bio Inc’s operating margin was -132.46% while its return on assets stood at -16.33% with a return of equity of -48.26%.

In Q2, 2Seventy Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 167.4%.

2Seventy Bio Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-4 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into 2Seventy Bio Inc’s profitability.

2Seventy Bio Inc stock is trading at a EV to sales ratio of 9.064 and a EV to EBITDA ratio of -2.0768. Its price to sales ratio in the trailing 12-months stood at 8.24.

2Seventy Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$705.71 million
Total Liabilities
$66.90 million
Operating Cash Flow
Capital Expenditure
$3.97 million
Dividend Payout Ratio

2Seventy Bio Inc ended 2023 with $705.71 million in total assets and $0 in total liabilities. Its intangible assets were valued at $705.71 million while shareholder equity stood at $367.50 million.

2Seventy Bio Inc ended 2023 with $0 in deferred long-term liabilities, $66.90 million in other current liabilities, 5000.00 in common stock, $-382757000.00 in retained earnings and $12.06 million in goodwill. Its cash balance stood at $95.99 million and cash and short-term investments were $282.84 million. The company’s total short-term debt was $11,872,000 while long-term debt stood at $0.

2Seventy Bio Inc’s total current assets stands at $333.67 million while long-term investments were $23.71 million and short-term investments were $186.85 million. Its net receivables were $44.10 million compared to accounts payable of $6.27 million and inventory worth $-44099000.00.

In 2023, 2Seventy Bio Inc's operating cash flow was $-64881000.00 while its capital expenditure stood at $3.97 million.

Comparatively, 2Seventy Bio Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

2Seventy Bio Inc stock is currently trading at $4.16 per share. It touched a 52-week high of $17.56 and a 52-week low of $17.56. Analysts tracking the stock have a 12-month average target price of $24.33.

Its 50-day moving average was $7.34 and 200-day moving average was $10.28 The short ratio stood at 5.21 indicating a short percent outstanding of 0%.

Around 165.6% of the company’s stock are held by insiders while 10171.6% are held by institutions.

Frequently Asked Questions About 2Seventy Bio Inc

The stock symbol (also called stock or share ticker) of 2Seventy Bio Inc is TSVT

The IPO of 2Seventy Bio Inc took place on 2021-11-03

Similar Industry Stocks (Biotechnology)

Last Price
Metro Brands Ltd (METROBRAND)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.


60 Binney Street, Cambridge, MA, United States, 02142